In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hybrigenics SA

www.hybrigenics.fr

Latest From Hybrigenics SA

Pipeline Watch: Xarelto, CVT-301 And Ameluz Phase III Readouts

Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Pipeline Watch Approvals

Pipeline Watch: Phase III Progress With Biosimilar Adalimumab And Trastuzumab

Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Pipeline Watch Clinical Trials

With Celgene Deal, Forma Makes First Foray Into Clinical Development

Forma Therapeutics has signed its largest and most ambitious oncology drug-discovery and development collaboration to date, in the exciting but early-stage area of protein homeostasis. Its new partner Celgene is no stranger to making big bets on promising cancer companies.

BioPharmaceutical Business Strategies

Hybrigenics to find protein-recycling enzyme targets for Servier

French firms Servier and Hybrigenics have signed a research collaboration under which Hybrigenics will look for new targets for Servier compounds from its research into deubiquitinating enzymes (DUBs), or "protein-recycling" enzymes.

Metabolic Disorders Cancer
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • Hybrigenics SA
  • Senior Management
  • Remi Delansorne, CEO
    Jean-Francois Dufour-Lamartinie, Head, Clinical R&D
    William Vickery, Head, Corp. & Bus. Dev.
  • Contact Info
  • Hybrigenics SA
    Phone: (33) 1 5810 3800
    3-5 impasse Reille
    Paris, 75014
    France
UsernamePublicRestriction

Register